通讯作者: 陈永法, cyf990@163.com

DOI：10.12201/bmr.202312.00008

Comparative Study on Grouping Rules in Centralized Volume-based Procurement of Chinese Patent Medicine

• 摘要：目的：系统梳理全国及各省、市（区）中成药集中带量采购（以下简称集采）有关政策文件，对比分析各地集采分组规则和方法，为完善我国中成药集采分组规则提供借鉴。 方法：通过文献分析法和比较分析法，对纳入研究的22部政策文本进行深入分析，对比、总结全国及省际联盟中成药集采的进展情况。 结果：全国和省际联盟中成药集采按照功能主治、给药途径、市场情况划分采购组，分组规则与药品剂型及质量的关联度不高；根据市场竞争格局划分竞价组别，忽视了部分中成药的创新价值，亦未考虑企业及其产品特有的品牌价值和中医药文化传播能力，分组规则的完备性有待提升。 结论：中成药剂型繁多，质量控制指标复杂，现有分组规则沿用化学药集采分组思路，缺乏以中成药价值为导向的顶层设计。建议采取多元分组方式，将现有入围规则中的技术评价“前置”，即在制定分组规则时考虑药品剂型、质量、创新价值、提升文化软实力等因素，并对分组规则做进一步完善与细化。

  关键词： 中成药；集中带量采购；分组规则; ; 

   

  Abstract: Objective: Comprehensively review national and provincial policies related to centralized procurement of Chinese patent medicines (CPM) and to compare the grouping rules and methods of centralized procurement in different regions, with the goal of providing guidance for enhancing the grouping rules for CPM. Methods: Through literature analysis and comparative analysis, the 22 policies included in the study were analyzed in depth, and the progress of centralized procurement of CPM in national and inter-provincial alliances was compared and summarized. Results: National and inter-provincial alliances’ centralized volume-based procurement of CPM divides procurement groups according to functional indications, route of administration, and market conditions. The grouping rules are not closely related to drug dosage forms and quality. Dividing bidding groups based on the market competition pattern ignores the innovative value of some CPM , and does not take into account the unique brand value of the company and its drugs. The completeness of the grouping rules needs to be improved. Conclusions: There are many dosage forms of CPM and complex quality control indicators. The existing grouping rules follow the idea of grouping chemical drugs and lack a top-level design oriented to the value of CPM. It is recommended to adopt a diversified grouping method and advance the technical evaluation link in the existing shortlisting rules. This means that factors such as drug dosage form, quality, innovation value, and improvement of cultural soft power should be considered when formulating grouping rules. At the same time, it is necessary to improve and refine the current grouping rules.

  Key words: Chinese patent medicines; centralized volume-based procurement; grouping rules.

  提交时间：2023-12-04

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 刘明珠, 路云. 基于间断时间序列的国家药品集中带量采购协议期满品种接续工作实施效果研究——以河北省为例. 2023. doi: 10.12201/bmr.202306.00007

  孙言, 朱正, 杨莉. 国家组织药品集中带量采购价格降幅影响因素分析. 2022. doi: 10.12201/bmr.202203.00008

  王彪, 张天天, 唐啸宇, 贾韵, 罗力. 国家组织药品带量采购政策的降价持续性研究. 2023. doi: 10.12201/bmr.202305.00008

  曾叙衡, 郑颐, 吕军, 宁玉玲, 励晓红. 实施高值医用耗材带量采购的SWOT分析——以上海市为例. 2020. doi: 10.12201/bmr.202010.00841

  宋佳, 范成鑫, 王婉晨, 艾旭峰, 刘馨璐, 李翠玉, 张玉杰, 李秋莎, 王安琪, 丰志强, 尹文强, 马东平. 利益相关者视角下我国药品集中带量采购政策研究——基于政策工具的文本分析. 2022. doi: 10.12201/bmr.202203.00006

  王彪, 张天天, 唐啸宇, 贾韵, 罗力. 我国集中带量采购中选药品价格的差异及区域分布研究. 2023. doi: 10.12201/bmr.202306.00008

  唐玉清, 李胤铭, 陈西卓, 薛天琴, 陈昊. 基于政策执行系统模型的药品集中采购政策执行分析. 2023. doi: 10.12201/bmr.202310.00002

  李钊, 赵珂, 周绿林, 陈盛. 国家集采常态化视域下药品集团采购模式对比及发展对策研究. 2021. doi: 10.12201/bmr.202109.00037

  孙文俊, 赵子寅, 成哲玉, 李慧宁, 祝贺. 药品集中采购政策对药品价格和使用影响的系统综述. 2023. doi: 10.12201/bmr.202303.00033

  李昱, 杨涛, 胡孔法. 基于层次社团划分算法的名老中医治疗肺癌的用药规律研究. 2021. doi: 10.12201/bmr.202110.00020

• 序号	提交日期	编号	操作
  1	2023-06-16	bmr.202312.00008V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论